Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We recently identified inositol hexakisphosphate kinase 2 (
IP6K2
) as a positive regulator of apoptosis. Overexpression of
IP6K2
enhances apoptosis induced by interferon-beta (IFN-beta) and cytotoxic agents in NIH-OVCAR-3 ovarian carcinoma cells. In this study, we contrast and compare IFN-beta and radiation-induced death, and show that
IP6K2
expression sensitizes tumor cells. Unirradiated NIH-OVCAR-3 cells transfected with
IP6K2
formed fewer colonies compared to unirradiated vector-expressing cells.
IP6K2
overexpression caused increased radiosensitivity, evidenced by decreased colony forming units (CFU). Both IFN-beta and radiation induced caspase 8. IFN-beta, but not gamma-irradiation, induced TRAIL in NIH-OVCAR-3 cells. Gamma irradiation, but not IFN-beta, induced DR4 mRNA. Apoptotic effects of IFN-beta or gamma-irradiation were blocked by expression of a dominant negative mutant death receptor 5 (DR5Delta) or by
Bcl-2
. Caspase-8 mRNA induction was more pronounced in
IP6K2
-expressing cells compared to vector-expressing cells. These data suggest that overexpression of
IP6K2
enhances sensitivity of some ovarian carcinomas to radiation and IFN-beta.
IP6K2
may function to enhance the expression and/or function of caspase 8 and DR4 following cell injury. Both IFN-beta and gamma-irradiation induce apoptosis through the extrinsic, receptor-mediated pathway, IFN-beta through TRAIL, radiation through DR4, and both through caspase 8. The function of both death inducers is positively regulated by
IP6K2
.
...
PMID:Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. 1189 21